NDA Journal 2021

Professor John Dillon:, Division of Molecular and Clinical Medicine, School of Medicine,University of Dundee, Ninewells Hospital , Dundee, UK Prof John Dillon is Professor of Hepatology and Gastroenterology and a principle investigator, in the Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, based at Ninewells hospital, Dundee. He is also an Honorary Consultant with NHS Tayside, leading a busy general hepatology service and a research group. He graduated in medicine from St Georges Hospital Medical School, University of London, and subsequently gained his MD based on research performed in the University of Edinburgh while a lecturer in Gastroenterology and Hepatology. His award winning research interests included; new pathways of care for patients with abnormal LFTs, for people infected with HCV, new therapies for HCV infection, as well as novel diagnostics and treatments for NAFLD. His research activities stretch from the bench to the bedside and out into the community. He has published over 200 peer reviewed original research papers. He chairs the Scottish HCV Action Plan Clinical Leads Group, is a member of the Scottish Government’s Ministerial advisory board for Blood Borne viruses and sexual health. He is Vice President for Hepatology of the British Society of Gastroenterology and was President of the Scottish Society of Gastroenterology. He previously led the development group of the UK consensus guidelines for HCV and has chaired the Hepatitis C SIGN guideline development group. He Chaired the SHAAP group that produced the recent “Alcohol -related liver disease: guidance for good practice” documents. He has delivered over 200 international lectures on liver disease Scientific Session Speaker Bios Dr. Thomas Marjot: Dr Thomas Marjot is a Hepatology Specialist Registrar and Wellcome Trust Clinical Research Training Fellow at the University of Oxford, UK. He has a research background in non-alcoholic fatty liver disease (NAFLD) with a particular focus on using experimental medicine techniques to explore pathways leading to hepatic steatosis. In March 2020 Dr Marjot set up the COVID Hep registry in partnership with the European Association for the Study of the Liver (EASL). This registry has since collected data for >1600 patients with COVID-19 and pre-existing liver disease from 32 countries and 150 centres across the world. This has allowed accurate characterisation of the COVID-19 disease course in patients with chronic liver disease, liver transplant recipients, and those with autoimmune liver disease on immunosuppression. This data has helped inform shielding and vaccination policy and Dr Marjot has co-authored the EASL position paper regarding the management of liver disease during the pandemic. Dr Marjot has also recently been awarded an EASL registry grant to investigate COVID-19 vaccine immunogenicity in patients with liver disease across multiple European sites. ” Dr. Steve Pandey: Mr Steve Pandey is a Consultant Colorectal Surgeon in Worcestershire. He is a laparoscopic colorectal surgeon with a particular interest in rectal cancers. Having graduated from the Armed Forces Medical College in India, Mr Pandey served as a Nepalese Army doctor for four years. He moved to the UK in 2000 and completed his Basic Surgical Training in Bristol and Higher Surgical Training in the West Midlands. He was appointed to his consultant job at Worcestershire Royal Hospital in 2010. The colorectal unit at Worcestershire Acute Hospitals NHS Trust is one of the busiest bowel cancer units in the country with a well established laparoscopic colorectal programme. The unit also has leading experience in novel laparoscopic rectal cancer techniques; laparoscopic extra levator APE (ELAPE) and Transanal TME (TaTME). Mr Pandey lives in Birmingham with his wife and two sons NDA UK JOURNAL, JULY 2021